数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
梁恒 男 Director and Lead Independent Director 63 未披露 2.14 2026-10-26
Helmut Jeggle 男 Director 56 未披露 888.93 2026-10-26
Derek DiRocco 男 Director 46 未披露 未持股 2026-10-26
Shanshan Xu 女 Chairman of the Board and Chief Executive Officer and Director and President 43 115.60万 862.38 2026-10-26
Christian Foerster 男 Director 48 未披露 未持股 2026-10-26

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Shanshan Xu 女 Chairman of the Board and Chief Executive Officer and Director and President 43 115.60万 862.38 2026-10-26
Thang Ho 男 Chief Development Officer 42 82.45万 22.84 2026-10-26
Crystal MacKay 女 Chief Operating Officer 48 未披露 未持股 2026-10-26
Jonathan I. Lieber 男 Chief Financial Officer 57 未披露 未持股 2026-10-26

董事简历

中英对照 |  中文 |  英文
梁恒

梁恒博士,男,美国国籍,博士学位,自2015年起担任公司首席财务官兼首席战略官。梁博士于1985年获得北京大学的化学学士学位,并分别于1992年及2001年获得芝加哥大学生物化学和分子生物学博士学位及工商管理硕士学位。1992年至2000年期间,梁博士任职于雅培公司(Abbott Laboratories),在该公司担任高级科研员,并是该公司某个制药行业内领先的结构开发团队的成员。在作为一名科学家的职业生涯中,梁博士撰写了1篇评论及13篇论文,其中6篇在《自然》(Nature)、《科学》(Science)及《美国国家科学院院报》(Proceedingsof National Academy of Sciences)上发表。2000年至2003年,梁博士担任PrudentialSecurities的助理分析师,负责范围涵盖主要和特种药品。此后,梁博士于JMPSecurities(2003年至2004年)及A.G.Edwards Inc.(2004年至2005年)担任高级生物技术分析师。2005年至2015年,梁博士任职于Leerink Partners LLC(现称SVB Leerink LLC),担任董事总经理兼生物技术权益研究负责人。梁博士目前为香港联交所生物科技咨询小组成员。2019年至今,梁博士担任MapKure公司董事,2020年至今,担任Tessera Therapeutics,Inc.董事。


Howard Liang has served as a member of Bambusa Therapeutics, Inc.'s board of directors since July 2026. From July 2021 to December 2025, Dr. Liang served in various leadership roles at Tessera Therapeutics, a privately held biotechnology company, including as President and previously as President and Chief Financial Officer. From July 2015 to June 2021, Dr. Liang served as the Chief Financial Officer and Chief Strategy Officer at BeiGene Ltd (now known as BeOne Medicines), a publicly traded biotechnology company. From 2005 to 2015, Dr. Liang served in various leadership roles of increasing responsibility at Leerink Partners LLC, an investment bank specializing in the healthcare industry, including most recently as Managing Director and Head of Biotechnology Equity Research. Dr. Liang served as a Senior Biotechnology Analyst at two investment banks: A.G. Edwards Inc. (now known as Wells Fargo Advisors), from 2004 to 2005, and JMP Securities (now known as Citizens JMP Securities, LLC), from 2003 to 2004. From 2000 to 2003, Dr. Liang served as an Associate Analyst at Prudential Securities, where he covered major and specialty pharmaceuticals. From 1992 to 2000, Dr. Liang was at Abbott Laboratories (now known as Abbvie), where he was a Senior Scientist and a member of a structure based discovery team. Dr. Liang has served on the board of directors of Tenacia Biotechnology, a privately held biotechnology company, since February 2023, and served as a member of the HKEx Biotech Advisory Panel from 2018 to 2024. Dr. Liang holds a B.S. in Chemistry from Peking University and both his M.B.A. and Ph.D. in Biochemistry and Molecular Biology from The University of Chicago.
梁恒博士,男,美国国籍,博士学位,自2015年起担任公司首席财务官兼首席战略官。梁博士于1985年获得北京大学的化学学士学位,并分别于1992年及2001年获得芝加哥大学生物化学和分子生物学博士学位及工商管理硕士学位。1992年至2000年期间,梁博士任职于雅培公司(Abbott Laboratories),在该公司担任高级科研员,并是该公司某个制药行业内领先的结构开发团队的成员。在作为一名科学家的职业生涯中,梁博士撰写了1篇评论及13篇论文,其中6篇在《自然》(Nature)、《科学》(Science)及《美国国家科学院院报》(Proceedingsof National Academy of Sciences)上发表。2000年至2003年,梁博士担任PrudentialSecurities的助理分析师,负责范围涵盖主要和特种药品。此后,梁博士于JMPSecurities(2003年至2004年)及A.G.Edwards Inc.(2004年至2005年)担任高级生物技术分析师。2005年至2015年,梁博士任职于Leerink Partners LLC(现称SVB Leerink LLC),担任董事总经理兼生物技术权益研究负责人。梁博士目前为香港联交所生物科技咨询小组成员。2019年至今,梁博士担任MapKure公司董事,2020年至今,担任Tessera Therapeutics,Inc.董事。
Howard Liang has served as a member of Bambusa Therapeutics, Inc.'s board of directors since July 2026. From July 2021 to December 2025, Dr. Liang served in various leadership roles at Tessera Therapeutics, a privately held biotechnology company, including as President and previously as President and Chief Financial Officer. From July 2015 to June 2021, Dr. Liang served as the Chief Financial Officer and Chief Strategy Officer at BeiGene Ltd (now known as BeOne Medicines), a publicly traded biotechnology company. From 2005 to 2015, Dr. Liang served in various leadership roles of increasing responsibility at Leerink Partners LLC, an investment bank specializing in the healthcare industry, including most recently as Managing Director and Head of Biotechnology Equity Research. Dr. Liang served as a Senior Biotechnology Analyst at two investment banks: A.G. Edwards Inc. (now known as Wells Fargo Advisors), from 2004 to 2005, and JMP Securities (now known as Citizens JMP Securities, LLC), from 2003 to 2004. From 2000 to 2003, Dr. Liang served as an Associate Analyst at Prudential Securities, where he covered major and specialty pharmaceuticals. From 1992 to 2000, Dr. Liang was at Abbott Laboratories (now known as Abbvie), where he was a Senior Scientist and a member of a structure based discovery team. Dr. Liang has served on the board of directors of Tenacia Biotechnology, a privately held biotechnology company, since February 2023, and served as a member of the HKEx Biotech Advisory Panel from 2018 to 2024. Dr. Liang holds a B.S. in Chemistry from Peking University and both his M.B.A. and Ph.D. in Biochemistry and Molecular Biology from The University of Chicago.
Helmut Jeggle

Helmut Jeggle是Bambusa Therapeutics,Inc.的联合创始人,自2024年6月起担任Bambusa Therapeutics,Inc.董事会成员。从2007年9月到2021年5月,Jeggle先生在私人控股的家族投资办公室ATHOS担任过各种领导职务,负责增加责任,包括最近担任普通合伙人。2021年5月,他创立了自己的家族办公室Salvia。投资工具Salvia GmbH,最初成立于2012年8月,是一家天使投资工具,自成立以来一直由他作为董事总经理管理。Salvia Investment GmbH是Salvia GmbH的100%子公司。Jeggle先生在多家上市公司的监事会任职,包括担任BioNTech监事会主席和4SC AG监事会成员,还在多家私营公司的监事会任职。Jeggle先生拥有应用科学大学Neu UlJeggle的工商管理学位和斯图加特管理与技术学院的工商管理硕士学位。


Helmut Jeggle is Bambusa Therapeutics, Inc.'s co founder and has served as a member of Bambusa Therapeutics, Inc.'s board of directors since June 2024. From September 2007 to May 2021, Mr. Jeggle served in various leadership roles of increasing responsibility at ATHOS, a privately held family investment office, including most recently as General Partner. In May 2021, he founded his own family office, Salvia. The investment vehicle Salvia GmbH, originally established as an angel investment vehicle in August 2012, has been managed by him as Managing Director since its incorporation. Salvia Investment GmbH is a 100% subsidiary of Salvia GmbH. Mr. Jeggle serves on the supervisory boards of several publicly traded companies, including as Chairman of the supervisory board of BioNTech and as a member of the supervisory board of 4SC AG, and also serves on the supervisory boards of several privately held companies. Mr. Jeggle holds a degree in business administration from the University of Applied Sciences Neu Ulm and an M.B.A. from the Stuttgart Institute of Management and Technology.
Helmut Jeggle是Bambusa Therapeutics,Inc.的联合创始人,自2024年6月起担任Bambusa Therapeutics,Inc.董事会成员。从2007年9月到2021年5月,Jeggle先生在私人控股的家族投资办公室ATHOS担任过各种领导职务,负责增加责任,包括最近担任普通合伙人。2021年5月,他创立了自己的家族办公室Salvia。投资工具Salvia GmbH,最初成立于2012年8月,是一家天使投资工具,自成立以来一直由他作为董事总经理管理。Salvia Investment GmbH是Salvia GmbH的100%子公司。Jeggle先生在多家上市公司的监事会任职,包括担任BioNTech监事会主席和4SC AG监事会成员,还在多家私营公司的监事会任职。Jeggle先生拥有应用科学大学Neu UlJeggle的工商管理学位和斯图加特管理与技术学院的工商管理硕士学位。
Helmut Jeggle is Bambusa Therapeutics, Inc.'s co founder and has served as a member of Bambusa Therapeutics, Inc.'s board of directors since June 2024. From September 2007 to May 2021, Mr. Jeggle served in various leadership roles of increasing responsibility at ATHOS, a privately held family investment office, including most recently as General Partner. In May 2021, he founded his own family office, Salvia. The investment vehicle Salvia GmbH, originally established as an angel investment vehicle in August 2012, has been managed by him as Managing Director since its incorporation. Salvia Investment GmbH is a 100% subsidiary of Salvia GmbH. Mr. Jeggle serves on the supervisory boards of several publicly traded companies, including as Chairman of the supervisory board of BioNTech and as a member of the supervisory board of 4SC AG, and also serves on the supervisory boards of several privately held companies. Mr. Jeggle holds a degree in business administration from the University of Applied Sciences Neu Ulm and an M.B.A. from the Stuttgart Institute of Management and Technology.
Derek DiRocco

Derek DiRocco自2025年2月起担任Bambusa Therapeutics,Inc.董事会成员。DiRocco博士目前是RA Capital Management,L.P.的合伙人,该公司是一家多阶段投资经理,致力于对医疗保健和生命科学公司进行基于证据的投资,自2013年7月以来,他在该公司担任过越来越多的职责。DiRocco博士目前在多家上市生物技术公司的董事会任职,包括自2021年11月起生效的Acrivon Therapeutics、自2022年6月起生效的Mineralys Therapeutics,Inc.以及自2024年10月起生效的Evommune。DiRocco博士此前曾在上市的临床阶段生物制药公司Achilles Therapeutics plc、康乃德生物制药控股有限公司、Werewolf Therapeutics, Inc. Therewolf Therapeutics,Inc.、89bio, Inc.和iTeos Therapeutics,Inc.的董事会任职,还曾在多家私营生物技术公司的董事会任职。DiRocco博士拥有圣十字学院生物学学士学位和华盛顿大学药理学博士学位,并在布莱根妇女医院/哈佛医学院进行博士后研究。


Derek DiRocco has served as a member of Bambusa Therapeutics, Inc.'s board of directors since February 2025. Dr. DiRocco is currently a Partner at RA Capital Management, L.P., a multi stage investment manager dedicated to evidence based investing in healthcare and life science companies, where he has served in various roles of increasing responsibility since July 2013. Dr. DiRocco currently serves on the boards of several publicly traded biotechnology companies, including Acrivon Therapeutics since November 2021, Mineralys Therapeutics, Inc. since June 2022, and Evommune since October 2024. Dr. DiRocco previously served on the boards of publicly traded clinical stage biopharmaceutical companies Achilles Therapeutics plc, Connect Biopharma Holdings Limited, Werewolf Therapeutics, Inc., 89bio, Inc., and iTeos Therapeutics, Inc., and also serves on the boards of several privately held biotechnology companies. Dr. DiRocco holds a B.A. in Biology from the College of the Holy Cross and a Ph.D. in Pharmacology from the University of Washington, and conducted his postdoctoral research at Brigham and Women's Hospital/Harvard Medical School.
Derek DiRocco自2025年2月起担任Bambusa Therapeutics,Inc.董事会成员。DiRocco博士目前是RA Capital Management,L.P.的合伙人,该公司是一家多阶段投资经理,致力于对医疗保健和生命科学公司进行基于证据的投资,自2013年7月以来,他在该公司担任过越来越多的职责。DiRocco博士目前在多家上市生物技术公司的董事会任职,包括自2021年11月起生效的Acrivon Therapeutics、自2022年6月起生效的Mineralys Therapeutics,Inc.以及自2024年10月起生效的Evommune。DiRocco博士此前曾在上市的临床阶段生物制药公司Achilles Therapeutics plc、康乃德生物制药控股有限公司、Werewolf Therapeutics, Inc. Therewolf Therapeutics,Inc.、89bio, Inc.和iTeos Therapeutics,Inc.的董事会任职,还曾在多家私营生物技术公司的董事会任职。DiRocco博士拥有圣十字学院生物学学士学位和华盛顿大学药理学博士学位,并在布莱根妇女医院/哈佛医学院进行博士后研究。
Derek DiRocco has served as a member of Bambusa Therapeutics, Inc.'s board of directors since February 2025. Dr. DiRocco is currently a Partner at RA Capital Management, L.P., a multi stage investment manager dedicated to evidence based investing in healthcare and life science companies, where he has served in various roles of increasing responsibility since July 2013. Dr. DiRocco currently serves on the boards of several publicly traded biotechnology companies, including Acrivon Therapeutics since November 2021, Mineralys Therapeutics, Inc. since June 2022, and Evommune since October 2024. Dr. DiRocco previously served on the boards of publicly traded clinical stage biopharmaceutical companies Achilles Therapeutics plc, Connect Biopharma Holdings Limited, Werewolf Therapeutics, Inc., 89bio, Inc., and iTeos Therapeutics, Inc., and also serves on the boards of several privately held biotechnology companies. Dr. DiRocco holds a B.A. in Biology from the College of the Holy Cross and a Ph.D. in Pharmacology from the University of Washington, and conducted his postdoctoral research at Brigham and Women's Hospital/Harvard Medical School.
Shanshan Xu

徐珊珊是Bambusa Therapeutics,Inc.的联合创始人,自Bambusa Therapeutics,Inc.成立以来一直担任Bambusa Therapeutics,Inc.的首席执行官和总裁以及Bambusa Therapeutics,Inc.董事会成员。自2026年9月起,她担任Bambusa Therapeutics,Inc.董事会主席。从2024年5月到2026年5月,徐博士担任BioNTech的特别顾问,该公司是一家上市的生物技术公司,专注于对抗癌症和传染病的免疫疗法。从2020年11月到2024年5月,徐博士在BioNTech担任过各种职责不断增加的领导职务,包括最近担任亚太和中国发展副总裁,然后担任外部创新副总裁。在加入BioNTech之前,2018年9月至2020年4月,徐博士在私人持股投资银行Berenberg Capital Markets担任高级生物技术研究分析师。徐博士于2017年至2018年在全球投资银行德意志银行证券公司担任副分析师,并于2016年至2017年在高宏集团公司(现称为TD 高宏集团)担任副分析师。徐博士拥有北京大学临床医学学士学位、加州大学欧文分校生物医学工程博士学位和麻省理工学院工商管理硕士学位。


Shanshan Xu is Bambusa Therapeutics, Inc.'s co founder and has served as Bambusa Therapeutics, Inc.'s Chief Executive Officer and President and a member of Bambusa Therapeutics, Inc.'s board of directors since Bambusa Therapeutics, Inc.'s Inception. Since September 2026, she has served as Chairperson of Bambusa Therapeutics, Inc.'s board of directors. From May 2024 to May 2026, Dr. Xu served as a Special Advisor to BioNTech, a publicly traded biotechnology company focused on immunotherapies against cancer and infectious disease. From November 2020 to May 2024, Dr. Xu held various leadership roles of increasing responsibility at BioNTech, including most recently as Vice President, Asia Pacific and China Development and then as Vice President, External Innovations. Prior to BioNTech, from September 2018 to April 2020, Dr. Xu served as Senior Biotech Research Analyst at Berenberg Capital Markets, a privately held investment bank. From 2017 to 2018, Dr. Xu served as an Associate Analyst at Deutsche Bank Securities, a global investment bank, and from 2016 to 2017, she served as an Associate Analyst at Cowen and Company (now known as TD Cowen). Dr. Xu holds a Bachelor of Medicine in Clinical Medicine from Peking University, a Ph.D. in Biomedical Engineering from the University of California, Irvine, and an M.B.A. from the Massachusetts Institute of Technology.
徐珊珊是Bambusa Therapeutics,Inc.的联合创始人,自Bambusa Therapeutics,Inc.成立以来一直担任Bambusa Therapeutics,Inc.的首席执行官和总裁以及Bambusa Therapeutics,Inc.董事会成员。自2026年9月起,她担任Bambusa Therapeutics,Inc.董事会主席。从2024年5月到2026年5月,徐博士担任BioNTech的特别顾问,该公司是一家上市的生物技术公司,专注于对抗癌症和传染病的免疫疗法。从2020年11月到2024年5月,徐博士在BioNTech担任过各种职责不断增加的领导职务,包括最近担任亚太和中国发展副总裁,然后担任外部创新副总裁。在加入BioNTech之前,2018年9月至2020年4月,徐博士在私人持股投资银行Berenberg Capital Markets担任高级生物技术研究分析师。徐博士于2017年至2018年在全球投资银行德意志银行证券公司担任副分析师,并于2016年至2017年在高宏集团公司(现称为TD 高宏集团)担任副分析师。徐博士拥有北京大学临床医学学士学位、加州大学欧文分校生物医学工程博士学位和麻省理工学院工商管理硕士学位。
Shanshan Xu is Bambusa Therapeutics, Inc.'s co founder and has served as Bambusa Therapeutics, Inc.'s Chief Executive Officer and President and a member of Bambusa Therapeutics, Inc.'s board of directors since Bambusa Therapeutics, Inc.'s Inception. Since September 2026, she has served as Chairperson of Bambusa Therapeutics, Inc.'s board of directors. From May 2024 to May 2026, Dr. Xu served as a Special Advisor to BioNTech, a publicly traded biotechnology company focused on immunotherapies against cancer and infectious disease. From November 2020 to May 2024, Dr. Xu held various leadership roles of increasing responsibility at BioNTech, including most recently as Vice President, Asia Pacific and China Development and then as Vice President, External Innovations. Prior to BioNTech, from September 2018 to April 2020, Dr. Xu served as Senior Biotech Research Analyst at Berenberg Capital Markets, a privately held investment bank. From 2017 to 2018, Dr. Xu served as an Associate Analyst at Deutsche Bank Securities, a global investment bank, and from 2016 to 2017, she served as an Associate Analyst at Cowen and Company (now known as TD Cowen). Dr. Xu holds a Bachelor of Medicine in Clinical Medicine from Peking University, a Ph.D. in Biomedical Engineering from the University of California, Irvine, and an M.B.A. from the Massachusetts Institute of Technology.
Christian Foerster

Christian Foerster自2026年7月起担任Bambusa Therapeutics,Inc.董事会成员。自2026年10月以来,福斯特先生一直担任私营软件公司neoshare AG的首席运营官。自2026年8月以来,Foerster先生在ATHOS担任顾问,ATHOS是一家私人控股的家族投资办公室,投资于生命科学行业,此前他曾在2024年10月至2026年7月期间担任董事总经理。2007年10月至2024年9月,Foerster先生在上市的电信、信息技术和消费电子产品公司诺基亚公司担任各种领导职务,负责增加责任,最近一次是在2021年1月至2024年9月期间担任云和网络服务首席运营官。福斯特先生拥有科学硕士学位(DIPL。Ing),慕尼黑应用科学大学工业工程与管理专业。


Christian Foerster has served as a member of Bambusa Therapeutics, Inc.'s board of directors since July 2026. Since October 2026, Mr. Foerster has served as Chief Operating Officer of neoshare AG, a privately held software company. Since August 2026, Mr. Foerster has served as a consultant at ATHOS, a privately held family investment office investing in the life science industry, where he previously served as Managing Director from October 2024 to July 2026. From October 2007 to September 2024, Mr. Foerster served in various leadership roles of increasing responsibility at Nokia Corporation, a publicly traded telecommunications, information technology, and consumer electronics corporation, including most recently as Chief Operating Officer, Cloud and Network Services from January 2021 to September 2024. Mr. Foerster holds a Master of Science (Dipl. Ing), Industrial Engineering & Management from Munich University of Applied Sciences.
Christian Foerster自2026年7月起担任Bambusa Therapeutics,Inc.董事会成员。自2026年10月以来,福斯特先生一直担任私营软件公司neoshare AG的首席运营官。自2026年8月以来,Foerster先生在ATHOS担任顾问,ATHOS是一家私人控股的家族投资办公室,投资于生命科学行业,此前他曾在2024年10月至2026年7月期间担任董事总经理。2007年10月至2024年9月,Foerster先生在上市的电信、信息技术和消费电子产品公司诺基亚公司担任各种领导职务,负责增加责任,最近一次是在2021年1月至2024年9月期间担任云和网络服务首席运营官。福斯特先生拥有科学硕士学位(DIPL。Ing),慕尼黑应用科学大学工业工程与管理专业。
Christian Foerster has served as a member of Bambusa Therapeutics, Inc.'s board of directors since July 2026. Since October 2026, Mr. Foerster has served as Chief Operating Officer of neoshare AG, a privately held software company. Since August 2026, Mr. Foerster has served as a consultant at ATHOS, a privately held family investment office investing in the life science industry, where he previously served as Managing Director from October 2024 to July 2026. From October 2007 to September 2024, Mr. Foerster served in various leadership roles of increasing responsibility at Nokia Corporation, a publicly traded telecommunications, information technology, and consumer electronics corporation, including most recently as Chief Operating Officer, Cloud and Network Services from January 2021 to September 2024. Mr. Foerster holds a Master of Science (Dipl. Ing), Industrial Engineering & Management from Munich University of Applied Sciences.

高管简历

中英对照 |  中文 |  英文
Shanshan Xu

徐珊珊是Bambusa Therapeutics,Inc.的联合创始人,自Bambusa Therapeutics,Inc.成立以来一直担任Bambusa Therapeutics,Inc.的首席执行官和总裁以及Bambusa Therapeutics,Inc.董事会成员。自2026年9月起,她担任Bambusa Therapeutics,Inc.董事会主席。从2024年5月到2026年5月,徐博士担任BioNTech的特别顾问,该公司是一家上市的生物技术公司,专注于对抗癌症和传染病的免疫疗法。从2020年11月到2024年5月,徐博士在BioNTech担任过各种职责不断增加的领导职务,包括最近担任亚太和中国发展副总裁,然后担任外部创新副总裁。在加入BioNTech之前,2018年9月至2020年4月,徐博士在私人持股投资银行Berenberg Capital Markets担任高级生物技术研究分析师。徐博士于2017年至2018年在全球投资银行德意志银行证券公司担任副分析师,并于2016年至2017年在高宏集团公司(现称为TD 高宏集团)担任副分析师。徐博士拥有北京大学临床医学学士学位、加州大学欧文分校生物医学工程博士学位和麻省理工学院工商管理硕士学位。


Shanshan Xu is Bambusa Therapeutics, Inc.'s co founder and has served as Bambusa Therapeutics, Inc.'s Chief Executive Officer and President and a member of Bambusa Therapeutics, Inc.'s board of directors since Bambusa Therapeutics, Inc.'s Inception. Since September 2026, she has served as Chairperson of Bambusa Therapeutics, Inc.'s board of directors. From May 2024 to May 2026, Dr. Xu served as a Special Advisor to BioNTech, a publicly traded biotechnology company focused on immunotherapies against cancer and infectious disease. From November 2020 to May 2024, Dr. Xu held various leadership roles of increasing responsibility at BioNTech, including most recently as Vice President, Asia Pacific and China Development and then as Vice President, External Innovations. Prior to BioNTech, from September 2018 to April 2020, Dr. Xu served as Senior Biotech Research Analyst at Berenberg Capital Markets, a privately held investment bank. From 2017 to 2018, Dr. Xu served as an Associate Analyst at Deutsche Bank Securities, a global investment bank, and from 2016 to 2017, she served as an Associate Analyst at Cowen and Company (now known as TD Cowen). Dr. Xu holds a Bachelor of Medicine in Clinical Medicine from Peking University, a Ph.D. in Biomedical Engineering from the University of California, Irvine, and an M.B.A. from the Massachusetts Institute of Technology.
徐珊珊是Bambusa Therapeutics,Inc.的联合创始人,自Bambusa Therapeutics,Inc.成立以来一直担任Bambusa Therapeutics,Inc.的首席执行官和总裁以及Bambusa Therapeutics,Inc.董事会成员。自2026年9月起,她担任Bambusa Therapeutics,Inc.董事会主席。从2024年5月到2026年5月,徐博士担任BioNTech的特别顾问,该公司是一家上市的生物技术公司,专注于对抗癌症和传染病的免疫疗法。从2020年11月到2024年5月,徐博士在BioNTech担任过各种职责不断增加的领导职务,包括最近担任亚太和中国发展副总裁,然后担任外部创新副总裁。在加入BioNTech之前,2018年9月至2020年4月,徐博士在私人持股投资银行Berenberg Capital Markets担任高级生物技术研究分析师。徐博士于2017年至2018年在全球投资银行德意志银行证券公司担任副分析师,并于2016年至2017年在高宏集团公司(现称为TD 高宏集团)担任副分析师。徐博士拥有北京大学临床医学学士学位、加州大学欧文分校生物医学工程博士学位和麻省理工学院工商管理硕士学位。
Shanshan Xu is Bambusa Therapeutics, Inc.'s co founder and has served as Bambusa Therapeutics, Inc.'s Chief Executive Officer and President and a member of Bambusa Therapeutics, Inc.'s board of directors since Bambusa Therapeutics, Inc.'s Inception. Since September 2026, she has served as Chairperson of Bambusa Therapeutics, Inc.'s board of directors. From May 2024 to May 2026, Dr. Xu served as a Special Advisor to BioNTech, a publicly traded biotechnology company focused on immunotherapies against cancer and infectious disease. From November 2020 to May 2024, Dr. Xu held various leadership roles of increasing responsibility at BioNTech, including most recently as Vice President, Asia Pacific and China Development and then as Vice President, External Innovations. Prior to BioNTech, from September 2018 to April 2020, Dr. Xu served as Senior Biotech Research Analyst at Berenberg Capital Markets, a privately held investment bank. From 2017 to 2018, Dr. Xu served as an Associate Analyst at Deutsche Bank Securities, a global investment bank, and from 2016 to 2017, she served as an Associate Analyst at Cowen and Company (now known as TD Cowen). Dr. Xu holds a Bachelor of Medicine in Clinical Medicine from Peking University, a Ph.D. in Biomedical Engineering from the University of California, Irvine, and an M.B.A. from the Massachusetts Institute of Technology.
Thang Ho

Thang Ho是Bambusa Therapeutics,Inc.的联合创始人,自2026年3月起担任Bambusa Therapeutics,Inc.的首席开发官。他此前曾于2025年10月至2026年3月担任Bambusa Therapeutics,Inc.的首席科学官,并于2024年4月至2025年10月担任Bambusa Therapeutics,Inc.的高级副总裁、发展科学主管。在加入Bambusa之前,从2021年11月到2024年4月,何博士在BioNTech担任过各种责任不断增加的领导职务,包括最近在2022年12月到2024年4月担任临床药理学和药物计量学主任。2021年4月至2021年11月,何博士在上市制药公司武田制药公司担任细胞疗法定量药理学主管副主任。从2020年3月到2021年4月,何博士在上市的生物技术公司福泰制药担任高级科学家。2018年10月至2020年3月,何博士在上市生物技术公司CytomX医疗担任高级科学家。何博士拥有阿肯色大学化学工程学士和硕士学位,匹兹堡大学化学工程学博士学位。


Thang Ho is Bambusa Therapeutics, Inc.'s co founder and has served as Bambusa Therapeutics, Inc.'s Chief Development Officer since March 2026. He previously served as Bambusa Therapeutics, Inc.'s Chief Scientific Officer from October 2025 to March 2026 and as Bambusa Therapeutics, Inc.'s Senior Vice President, Head of Development Science from April 2024 to October 2025. Prior to joining Bambusa, from November 2021 to April 2024, Dr. Ho served in various leadership roles of increasing responsibility at BioNTech, including most recently Director, Clinical Pharmacology and Pharmacometrics from December 2022 to April 2024. From April 2021 to November 2021, Dr. Ho was Associate Director, Quantitative Pharmacology Lead, Cell Therapies, at Takeda Pharmaceutical Company, a publicly traded pharmaceutical company. From March 2020 to April 2021, Dr. Ho served as Senior Scientist at Vertex Pharmaceuticals, a publicly traded biotechnology company. From October 2018 to March 2020, Dr. Ho served as Senior Scientist at CytomX Therapeutics, a public biotechnology company. Dr. Ho holds a B.S. and an M.S. in Chemical Engineering from the University of Arkansas, and a Ph.D. in Chemical Engineering from the University of Pittsburgh.
Thang Ho是Bambusa Therapeutics,Inc.的联合创始人,自2026年3月起担任Bambusa Therapeutics,Inc.的首席开发官。他此前曾于2025年10月至2026年3月担任Bambusa Therapeutics,Inc.的首席科学官,并于2024年4月至2025年10月担任Bambusa Therapeutics,Inc.的高级副总裁、发展科学主管。在加入Bambusa之前,从2021年11月到2024年4月,何博士在BioNTech担任过各种责任不断增加的领导职务,包括最近在2022年12月到2024年4月担任临床药理学和药物计量学主任。2021年4月至2021年11月,何博士在上市制药公司武田制药公司担任细胞疗法定量药理学主管副主任。从2020年3月到2021年4月,何博士在上市的生物技术公司福泰制药担任高级科学家。2018年10月至2020年3月,何博士在上市生物技术公司CytomX医疗担任高级科学家。何博士拥有阿肯色大学化学工程学士和硕士学位,匹兹堡大学化学工程学博士学位。
Thang Ho is Bambusa Therapeutics, Inc.'s co founder and has served as Bambusa Therapeutics, Inc.'s Chief Development Officer since March 2026. He previously served as Bambusa Therapeutics, Inc.'s Chief Scientific Officer from October 2025 to March 2026 and as Bambusa Therapeutics, Inc.'s Senior Vice President, Head of Development Science from April 2024 to October 2025. Prior to joining Bambusa, from November 2021 to April 2024, Dr. Ho served in various leadership roles of increasing responsibility at BioNTech, including most recently Director, Clinical Pharmacology and Pharmacometrics from December 2022 to April 2024. From April 2021 to November 2021, Dr. Ho was Associate Director, Quantitative Pharmacology Lead, Cell Therapies, at Takeda Pharmaceutical Company, a publicly traded pharmaceutical company. From March 2020 to April 2021, Dr. Ho served as Senior Scientist at Vertex Pharmaceuticals, a publicly traded biotechnology company. From October 2018 to March 2020, Dr. Ho served as Senior Scientist at CytomX Therapeutics, a public biotechnology company. Dr. Ho holds a B.S. and an M.S. in Chemical Engineering from the University of Arkansas, and a Ph.D. in Chemical Engineering from the University of Pittsburgh.
Crystal MacKay

Crystal MacKay自2026年7月起担任Bambusa Therapeutics,Inc.的首席运营官。她曾于2025年9月至2026年7月担任Bambusa Therapeutics,Inc.财务和业务运营高级副总裁,2025年8月至2025年9月担任Bambusa Therapeutics,Inc.财务和业务运营副总裁,并于2024年10月至2025年8月担任Bambusa Therapeutics,Inc.副总裁兼参谋长。在加入Bambusa之前,从2019年8月到2023年9月,MacKay女士在私人控股的金融服务公司BTIG担任过越来越多的职务,包括最近在2023年1月到2023年9月担任的医疗保健投资银行业务总监。2018年7月至2018年9月,MacKay女士担任计费和管理式护理战略部门董事,2018年10月至2019年8月,MacKay女士在当时上市的诊断公司Oxford Immunotec(被珀金埃尔默收购,现名为Revvity)担任业务运营部门董事。2016年2月至2018年7月,MacKay女士在私营诊断实验室Strata Pathology Services担任收入周期和管理式护理合同总监。从2004年3月到2015年10月,MacKay女士在私人控股的临床毒理学实验室Calloway Labs担任各种职责,包括担任董事会成员。MacKay女士拥有马萨诸塞大学商业传播学士学位。


Crystal MacKay has served as Bambusa Therapeutics, Inc.'s Chief Operating Officer since July 2026. She previously served as Bambusa Therapeutics, Inc.'s Senior Vice President, Finance and Business Operations from September 2025 to July 2026, Bambusa Therapeutics, Inc.'s Vice President, Finance and Business Operations from August 2025 to September 2025, and Bambusa Therapeutics, Inc.'s Vice President and Chief of Staff from October 2024 to August 2025. Prior to joining Bambusa, from August 2019 to September 2023, Ms. MacKay served in various roles of increasing responsibility at BTIG, a privately held financial services firm, including most recently Director of Healthcare Investment Banking from January 2023 to September 2023. From July 2018 to September 2018 Ms. MacKay served as Director, Billing and Managed Care Strategy, and from October 2018 to August 2019, Ms. MacKay served as Director, Business Operations, at Oxford Immunotec (acquired by PerkinElmer, now known as Revvity), a diagnostics company that was publicly traded at the time. From February 2016 to July 2018, Ms. MacKay served as Director of Revenue Cycle and Managed Care Contracting at Strata Pathology Services, a privately held diagnostic laboratory. From March 2004 to October 2015, Ms. MacKay served in various roles of increasing responsibility at Calloway Labs, a privately held clinical toxicology laboratory, including as a member of the board of directors. Ms. MacKay holds a B.A. in Business Communications from the University of Massachusetts.
Crystal MacKay自2026年7月起担任Bambusa Therapeutics,Inc.的首席运营官。她曾于2025年9月至2026年7月担任Bambusa Therapeutics,Inc.财务和业务运营高级副总裁,2025年8月至2025年9月担任Bambusa Therapeutics,Inc.财务和业务运营副总裁,并于2024年10月至2025年8月担任Bambusa Therapeutics,Inc.副总裁兼参谋长。在加入Bambusa之前,从2019年8月到2023年9月,MacKay女士在私人控股的金融服务公司BTIG担任过越来越多的职务,包括最近在2023年1月到2023年9月担任的医疗保健投资银行业务总监。2018年7月至2018年9月,MacKay女士担任计费和管理式护理战略部门董事,2018年10月至2019年8月,MacKay女士在当时上市的诊断公司Oxford Immunotec(被珀金埃尔默收购,现名为Revvity)担任业务运营部门董事。2016年2月至2018年7月,MacKay女士在私营诊断实验室Strata Pathology Services担任收入周期和管理式护理合同总监。从2004年3月到2015年10月,MacKay女士在私人控股的临床毒理学实验室Calloway Labs担任各种职责,包括担任董事会成员。MacKay女士拥有马萨诸塞大学商业传播学士学位。
Crystal MacKay has served as Bambusa Therapeutics, Inc.'s Chief Operating Officer since July 2026. She previously served as Bambusa Therapeutics, Inc.'s Senior Vice President, Finance and Business Operations from September 2025 to July 2026, Bambusa Therapeutics, Inc.'s Vice President, Finance and Business Operations from August 2025 to September 2025, and Bambusa Therapeutics, Inc.'s Vice President and Chief of Staff from October 2024 to August 2025. Prior to joining Bambusa, from August 2019 to September 2023, Ms. MacKay served in various roles of increasing responsibility at BTIG, a privately held financial services firm, including most recently Director of Healthcare Investment Banking from January 2023 to September 2023. From July 2018 to September 2018 Ms. MacKay served as Director, Billing and Managed Care Strategy, and from October 2018 to August 2019, Ms. MacKay served as Director, Business Operations, at Oxford Immunotec (acquired by PerkinElmer, now known as Revvity), a diagnostics company that was publicly traded at the time. From February 2016 to July 2018, Ms. MacKay served as Director of Revenue Cycle and Managed Care Contracting at Strata Pathology Services, a privately held diagnostic laboratory. From March 2004 to October 2015, Ms. MacKay served in various roles of increasing responsibility at Calloway Labs, a privately held clinical toxicology laboratory, including as a member of the board of directors. Ms. MacKay holds a B.A. in Business Communications from the University of Massachusetts.
Jonathan I. Lieber

Jonathan I. Lieber自2021年9月起担任Applied Genetic Technologies Corporation首席财务官。从2018年12月到2021年9月,Lieber先生担任生物技术融资和会计咨询公司Danforth Advisors的董事总经理。Lieber先生曾于2015年6月至2018年12月担任Histogenics Corporation的首席财务官,该公司是一家专注于开发恢复性细胞疗法的生物制药公司。在此之前,他于2014年1月至2015年6月担任Metamark Genetics,Inc.的高级副总裁兼首席财务官,Metamark Genetics,Inc.是一家专注于泌尿科的私营分子诊断公司。2012年9月至2013年9月,Lieber先生担任生命科学行业高价值耗材制造商和供应商Repligen Corporation的首席财务官和财务主管。2009年6月至2012年5月,Lieber先生担任Xcellerex,Inc.的首席财务官和财务主管,该公司是一家私营公司,从事为生物制药行业制造和销售资本设备和相关消耗品。自2020年6月以来,Lieber先生一直在专注于癌症的生物技术公司Salarius制药的董事会任职。Lieber先生获得了纽约大学斯特恩商学院的金融学工商管理硕士学位和理学学士学位。


Jonathan I. Lieber has served as Bambusa Therapeutics, Inc.'s Chief Financial Officer since September 2026. He is also currently serving part time as Chief Financial Officer of Rallybio Corporation, a clinical stage biotechnology company, a position he has held since February 2023. Prior to joining Bambusa, from September 2021 to November 2022, Mr. Lieber served as the Chief Financial Officer of Applied Genetic Technologies Corporation, a publicly traded clinical stage biotechnology company. From December 2018 to September 2021, Mr. Lieber was a Managing Director at Danforth Advisors, a firm providing strategic and operational finance and accounting for life science companies. From July 2015 until December 2018, Mr. Lieber served as Chief Financial Officer of Histogenics Corporation, a publicly traded cell therapy company. Mr. Lieber also previously served as the Chief Financial Officer of Metamark Genetics, Inc., Repligen Corporation, Xcellerex, Inc., and Altus Pharmaceuticals. Mr. Lieber began his career in healthcare as an investment banker at Salomon Brothers/Salomon Smith Barney and SG Cowen. He has been a member of the board of directors of Decoy Therapeutics, Inc., a publicly traded biotechnology company, since June 2020, Mindwalk Holdings Corp., a publicly traded bio native AI company, since July 2025, and Zola Therapeutics, a privately held biotechnology company, since February 2024. Mr. Lieber holds a B.S. in business administration and finance from Boston University and an M.B.A. in finance from New York University's Leonard N. Stern School of Business.
Jonathan I. Lieber自2021年9月起担任Applied Genetic Technologies Corporation首席财务官。从2018年12月到2021年9月,Lieber先生担任生物技术融资和会计咨询公司Danforth Advisors的董事总经理。Lieber先生曾于2015年6月至2018年12月担任Histogenics Corporation的首席财务官,该公司是一家专注于开发恢复性细胞疗法的生物制药公司。在此之前,他于2014年1月至2015年6月担任Metamark Genetics,Inc.的高级副总裁兼首席财务官,Metamark Genetics,Inc.是一家专注于泌尿科的私营分子诊断公司。2012年9月至2013年9月,Lieber先生担任生命科学行业高价值耗材制造商和供应商Repligen Corporation的首席财务官和财务主管。2009年6月至2012年5月,Lieber先生担任Xcellerex,Inc.的首席财务官和财务主管,该公司是一家私营公司,从事为生物制药行业制造和销售资本设备和相关消耗品。自2020年6月以来,Lieber先生一直在专注于癌症的生物技术公司Salarius制药的董事会任职。Lieber先生获得了纽约大学斯特恩商学院的金融学工商管理硕士学位和理学学士学位。
Jonathan I. Lieber has served as Bambusa Therapeutics, Inc.'s Chief Financial Officer since September 2026. He is also currently serving part time as Chief Financial Officer of Rallybio Corporation, a clinical stage biotechnology company, a position he has held since February 2023. Prior to joining Bambusa, from September 2021 to November 2022, Mr. Lieber served as the Chief Financial Officer of Applied Genetic Technologies Corporation, a publicly traded clinical stage biotechnology company. From December 2018 to September 2021, Mr. Lieber was a Managing Director at Danforth Advisors, a firm providing strategic and operational finance and accounting for life science companies. From July 2015 until December 2018, Mr. Lieber served as Chief Financial Officer of Histogenics Corporation, a publicly traded cell therapy company. Mr. Lieber also previously served as the Chief Financial Officer of Metamark Genetics, Inc., Repligen Corporation, Xcellerex, Inc., and Altus Pharmaceuticals. Mr. Lieber began his career in healthcare as an investment banker at Salomon Brothers/Salomon Smith Barney and SG Cowen. He has been a member of the board of directors of Decoy Therapeutics, Inc., a publicly traded biotechnology company, since June 2020, Mindwalk Holdings Corp., a publicly traded bio native AI company, since July 2025, and Zola Therapeutics, a privately held biotechnology company, since February 2024. Mr. Lieber holds a B.S. in business administration and finance from Boston University and an M.B.A. in finance from New York University's Leonard N. Stern School of Business.